{"id":76358,"date":"2026-08-24T11:36:15","date_gmt":"2026-08-24T03:36:15","guid":{"rendered":"https:\/\/flcube.com\/?p=76358"},"modified":"2026-08-24T11:36:16","modified_gmt":"2026-08-24T03:36:16","slug":"hengrui-pharma-wins-nmpa-approval-for-three-clinical-trials-led-by-first-in-class-shr-7012-for-cutaneous-lupus","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=76358","title":{"rendered":"Hengrui Pharma Wins NMPA Approval for Three Clinical Trials Led by First\u2011in\u2011Class SHR\u20117012 for Cutaneous Lupus"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Jiangsu Hengrui Pharmaceuticals Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/600276:SHA\">SHA: 600276<\/a>; <a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/1276:HKG\">HKG: 1276<\/a>) announced that three investigational drugs \u2014 <strong>SHR\u20117012 Injection<\/strong>, <strong>HRS\u20113095 Tablets<\/strong> and <strong>SHR\u20118203 Injection<\/strong> \u2014 have received clinical trial approval from China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong>, expanding the company&#8217;s pipeline across autoimmune disease and oncology with two potential first\u2011in\u2011class assets.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Investigational New Drug (IND) \u2013 clinical trial approval<\/td><\/tr><tr><td><strong>Products<\/strong><\/td><td>SHR\u20117012 Injection; HRS\u20113095 Tablets; SHR\u20118203 Injection<\/td><\/tr><tr><td><strong>Therapeutic Areas<\/strong><\/td><td>Autoimmune (cutaneous lupus, ITP, AIHA); oncology (advanced solid tumors)<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>24 Aug 2026<\/td><\/tr><tr><td><strong>Novelty<\/strong><\/td><td>SHR\u20117012 and SHR\u20118203 have no same\u2011mechanism\/similar product approved in China or globally<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-shr-7012-injection-cutaneous-lupus-erythematosus\" class=\"wp-block-heading\">SHR\u20117012 Injection \u2013 Cutaneous Lupus Erythematosus<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Type:<\/strong> Innovative biologic independently developed by Hengrui Pharma<\/li>\n\n\n\n<li><strong>Indication:<\/strong> Cutaneous lupus erythematosus<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> <strong>No drug targeting the same pathway has been approved in China or globally<\/strong> \u2014 a potential first\u2011in\u2011class asset<\/li>\n\n\n\n<li><strong>Unmet Need:<\/strong> Cutaneous lupus remains underserved, with limited approved targeted therapies worldwide<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-hrs-3095-tablets-autoimmune-cytopenias\" class=\"wp-block-heading\">HRS\u20113095 Tablets \u2013 Autoimmune Cytopenias<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Type:<\/strong> Small\u2011molecule compound independently developed by Hengrui Pharma, targeting immune cells<\/li>\n\n\n\n<li><strong>Preclinical Evidence:<\/strong> HRS\u20113095 effectively inhibited <strong>antibody\u2011mediated blood cell destruction<\/strong> in preclinical studies<\/li>\n\n\n\n<li><strong>Current Status:<\/strong> Already in <strong>Phase 2 trials for chronic spontaneous urticaria<\/strong><\/li>\n\n\n\n<li><strong>Newly Approved Indications:<\/strong>\n<ul class=\"wp-block-list\">\n<li><strong>Primary immune thrombocytopenia (ITP)<\/strong><\/li>\n\n\n\n<li><strong>Autoimmune hemolytic anemia (AIHA)<\/strong><\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Strategic Significance:<\/strong> Extends an in\u2011clinic asset into two additional autoimmune cytopenia indications, leveraging a shared mechanism across diseases<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-shr-8203-injection-advanced-solid-tumors\" class=\"wp-block-heading\">SHR\u20118203 Injection \u2013 Advanced Solid Tumors<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Type:<\/strong> Innovative anti\u2011tumor biologic independently developed by Hengrui Pharma<\/li>\n\n\n\n<li><strong>Indication:<\/strong> Advanced solid tumors<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> <strong>No similar product approved in China or globally to date<\/strong> \u2014 a second potential first\u2011in\u2011class candidate in this batch<\/li>\n\n\n\n<li><strong>Portfolio Fit:<\/strong> Broadens Hengrui&#8217;s oncology pipeline beyond its established marketed franchise<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First\u2011in\u2011Class Pipeline Depth:<\/strong> Two of the three newly approved programs (SHR\u20117012, SHR\u20118203) target mechanisms with no approved competitor anywhere globally, signaling Hengrui&#8217;s strategic shift from fast\u2011follow biosimilars and me\u2011too assets toward differentiated innovation.<\/li>\n\n\n\n<li><strong>Autoimmune Platform Build\u2011Out:<\/strong> HRS\u20113095&#8217;s expansion from chronic spontaneous urticaria into ITP and AIHA mirrors a platform strategy \u2014 one immune\u2011cell\u2011targeting molecule, multiple antibody\u2011mediated indications \u2014 which, if validated clinically, could amortize development cost across several markets.<\/li>\n\n\n\n<li><strong>China Regulatory Tailwind:<\/strong> Three IND approvals in a single announcement underscores NMPA&#8217;s continued support for domestic innovative drug development and Hengrui&#8217;s standing as one of China&#8217;s largest R&amp;D\u2011driven pharmaceutical companies by pipeline volume.<\/li>\n\n\n\n<li><strong>Next Milestones:<\/strong> Investors will watch for Phase 2 data readouts in urticaria, first\u2011in\u2011human trial initiation for SHR\u20117012 and SHR\u20118203, and any subsequent NMPA designations.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development, regulatory timelines, and commercial potential for SHR\u20117012, HRS\u20113095 and SHR\u20118203. Actual results may differ due to risks including clinical trial outcomes, regulatory requirements, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/600276_20260821_NGKR.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600276_20260821_NGKR.\"><\/object><a id=\"wp-block-file--media-3d9bad80-abe9-49ee-9f26-6e6b46a89273\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/600276_20260821_NGKR.pdf\">600276_20260821_NGKR<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/600276_20260821_NGKR.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-3d9bad80-abe9-49ee-9f26-6e6b46a89273\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that three investigational drugs \u2014&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[62,2586,4228,852],"class_list":["post-76358","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-hengrui-pharmaceuticals","tag-hkg-1276","tag-sha-600276"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hengrui Pharma Wins NMPA Approval for Three Clinical Trials Led by First\u2011in\u2011Class SHR\u20117012 for Cutaneous Lupus - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that three investigational drugs \u2014 SHR\u20117012 Injection, HRS\u20113095 Tablets and SHR\u20118203 Injection \u2014 have received clinical trial approval from China&#039;s National Medical Products Administration (NMPA), expanding the company&#039;s pipeline across autoimmune disease and oncology with two potential first\u2011in\u2011class assets.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=76358\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hengrui Pharma Wins NMPA Approval for Three Clinical Trials Led by First\u2011in\u2011Class SHR\u20117012 for Cutaneous Lupus\" \/>\n<meta property=\"og:description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that three investigational drugs \u2014 SHR\u20117012 Injection, HRS\u20113095 Tablets and SHR\u20118203 Injection \u2014 have received clinical trial approval from China&#039;s National Medical Products Administration (NMPA), expanding the company&#039;s pipeline across autoimmune disease and oncology with two potential first\u2011in\u2011class assets.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=76358\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-24T03:36:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-24T03:36:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76358#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76358\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hengrui Pharma Wins NMPA Approval for Three Clinical Trials Led by First\u2011in\u2011Class SHR\u20117012 for Cutaneous Lupus\",\"datePublished\":\"2026-08-24T03:36:15+00:00\",\"dateModified\":\"2026-08-24T03:36:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76358\"},\"wordCount\":480,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Hengrui Pharmaceuticals\",\"HKG: 1276\",\"SHA: 600276\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=76358#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76358\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=76358\",\"name\":\"Hengrui Pharma Wins NMPA Approval for Three Clinical Trials Led by First\u2011in\u2011Class SHR\u20117012 for Cutaneous Lupus - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-24T03:36:15+00:00\",\"dateModified\":\"2026-08-24T03:36:16+00:00\",\"description\":\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that three investigational drugs \u2014 SHR\u20117012 Injection, HRS\u20113095 Tablets and SHR\u20118203 Injection \u2014 have received clinical trial approval from China's National Medical Products Administration (NMPA), expanding the company's pipeline across autoimmune disease and oncology with two potential first\u2011in\u2011class assets.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76358#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=76358\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76358#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hengrui Pharma Wins NMPA Approval for Three Clinical Trials Led by First\u2011in\u2011Class SHR\u20117012 for Cutaneous Lupus\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hengrui Pharma Wins NMPA Approval for Three Clinical Trials Led by First\u2011in\u2011Class SHR\u20117012 for Cutaneous Lupus - Insight, China&#039;s Pharmaceutical Industry","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that three investigational drugs \u2014 SHR\u20117012 Injection, HRS\u20113095 Tablets and SHR\u20118203 Injection \u2014 have received clinical trial approval from China's National Medical Products Administration (NMPA), expanding the company's pipeline across autoimmune disease and oncology with two potential first\u2011in\u2011class assets.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=76358","og_locale":"en_US","og_type":"article","og_title":"Hengrui Pharma Wins NMPA Approval for Three Clinical Trials Led by First\u2011in\u2011Class SHR\u20117012 for Cutaneous Lupus","og_description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that three investigational drugs \u2014 SHR\u20117012 Injection, HRS\u20113095 Tablets and SHR\u20118203 Injection \u2014 have received clinical trial approval from China's National Medical Products Administration (NMPA), expanding the company's pipeline across autoimmune disease and oncology with two potential first\u2011in\u2011class assets.","og_url":"https:\/\/flcube.com\/?p=76358","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-24T03:36:15+00:00","article_modified_time":"2026-08-24T03:36:16+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=76358#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=76358"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hengrui Pharma Wins NMPA Approval for Three Clinical Trials Led by First\u2011in\u2011Class SHR\u20117012 for Cutaneous Lupus","datePublished":"2026-08-24T03:36:15+00:00","dateModified":"2026-08-24T03:36:16+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=76358"},"wordCount":480,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","Hengrui Pharmaceuticals","HKG: 1276","SHA: 600276"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=76358#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=76358","url":"https:\/\/flcube.com\/?p=76358","name":"Hengrui Pharma Wins NMPA Approval for Three Clinical Trials Led by First\u2011in\u2011Class SHR\u20117012 for Cutaneous Lupus - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-24T03:36:15+00:00","dateModified":"2026-08-24T03:36:16+00:00","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that three investigational drugs \u2014 SHR\u20117012 Injection, HRS\u20113095 Tablets and SHR\u20118203 Injection \u2014 have received clinical trial approval from China's National Medical Products Administration (NMPA), expanding the company's pipeline across autoimmune disease and oncology with two potential first\u2011in\u2011class assets.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=76358#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=76358"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=76358#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hengrui Pharma Wins NMPA Approval for Three Clinical Trials Led by First\u2011in\u2011Class SHR\u20117012 for Cutaneous Lupus"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76358","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=76358"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76358\/revisions"}],"predecessor-version":[{"id":76361,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76358\/revisions\/76361"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=76358"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=76358"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=76358"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}